5 withdrawn. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Withdrawn 5 |
Follow palbociclib: new trials by email Literature Review of palbociclib trials Research Report on palbociclib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Avelumab, Palbociclib and Axitinib in Advanced RCC Axitinib, Palbociclib, Avelumab - Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Withdrawn | Bradley A. McGregor, MD | 2024-05-31 | 2023-09-07 | |
| Phase II Safety Single-arm Study of CDK4/6 Inhibition With Palbociclib in Hospitalized, Moderate COVID-19 Cases to Prevent Thromboinflammation Palbociclib - COVID-19 | Phase 2 | Withdrawn | biotx.ai GmbH | 2022-04-21 | 2022-11-07 | |
| CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions), Letrozole 2.5Mg Tab, Palbociclib 125mg - Breast Cancer | Phase 2 | Withdrawn | Weill Medical College of Cornell University | 2020-03-04 | 2020-09-21 | |
| Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer Copanlisib, Fulvestrant, Laboratory Biomarker Analysis - Estrogen Receptor Positive, HER2/Neu Negative | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2018-08-07 | 2018-08-14 | |
| Histology-Independent Study of Palbociclib in Patients With Advanced Cancer Palbociclib 125mg - Cancer, Advanced | Phase 2 | Withdrawn | Razelle Kurzrock, MD | 2018-07-01 | 2018-06-21 |
Breast Neoplasms (1) · COVID-19 (1) · Lymphoma, Follicular (1) · Neoplasms (1)
Bradley A. McGregor, MD (1) · National Cancer Institute (NCI) (1) · Razelle Kurzrock, MD (1) · Weill Medical College of Cornell University (1) · biotx.ai GmbH (1)
Germany (1) · United States (1)
Bradley McGregor, MD (1) · Cynthia Ma (1) · Mark Reinwald, PD Dr. med. (1) · Scott Lippman, MD (1) · Silvia Formenti, M.D. (1)
UM1CA186704 (1)